That’s because the British molecular diagnostics maker, which has operations in Maynard, Mass., wants to move to a direct sales force for its business in the U.S.
The deal had Thermo Fisher subsidiary Fisher HealthCare distributing Osmetech’s eSensor XT-8 platform in the States. The British firm said it plans to expand its direct-sales force here over the next three years, targeting molecular diagnostic testing laboratories and clinics established to dose and monitor the administration of therapeutic drugs.
The executive suite at the company’s London headquarters has been a turbulent place in recent months, as three new occupants passed through the corner suite in two months.
Earlier this month, Jon Faiz Kayyem, a board member and major stakeholder, was tapped to man the helm on an interim basis until a permanent replacement is found.
The move comes just six weeks after Osmetech announced that former CEO James White would be stepping down and new board chairman Christopher Gleeson would fill be filling in as CEO. Gleeson had served the company as joint chief executive, along with Kayyem, who will now fill the role on his own.